Catalyst Wire Dossier Catalyst Wire Dossier

ABP-234

pembrolizumab biosimilar · Amgen
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ABP-234, covering 2026-04-01 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer [Phase 3]

See pricing